CARLSBAD, Calif., March 29, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:
Data from Two Mipomersen Phase 3 Trials presented at ACC
Tuesday, April 05, 2011 at 1:00 p.m. ET / 10:00 a.m. PT
Live on the Internet. Simply log onto our Web site listed above.
Director, Corporate Communications
Amy Blackley, Ph.D.
Assistant Director, Corporate Communications
If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 24 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis has designed and executed a patent strategy that has provided the Company with strong and extensive protection for Isis' drugs and technology. Additional information about Isis is available at www.isispharm.com.
SOURCE Isis Pharmaceuticals, Inc.